secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harvard Apparatus Regenerative Technology, Inc. (HRGN)
CIK:        0001563665
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001104659-22-088054
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biostage appoints Joseph Damasio as CFO; $250K salary, 116K-share option grant
------------------------------------------------------------------------------

- Mr. Damasio appointed CFO effective August 8, 2022; brings capital raising and biotech finance experience.
- Initial annual base salary of $250,000, plus $25,000 bonus for remainder of FY2022 subject to milestones.
- Granted nonqualified stock option for 116,156 shares vesting equally over four years.
- Company intends to relist on NASDAQ and start clinical trial for esophageal implant.
- Interim CEO David Green highlights Damasio's skills for operational management and capital raises.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563665/000110465922088054/0001104659-22-088054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563665/000110465922088054/tm2222955d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-088054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer